<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159301</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01435</org_study_id>
    <secondary_id>NCI-2011-01435</secondary_id>
    <secondary_id>CDR0000675600</secondary_id>
    <secondary_id>I-165409</secondary_id>
    <secondary_id>8272</secondary_id>
    <nct_id>NCT01159301</nct_id>
  </id_info>
  <brief_title>Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I Study of Sorafenib in Combination With the Histone Deacetylase Inhibitor, Entinostat in Patients With Advanced Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and the best dose of entinostat when given&#xD;
      together with sorafenib tosylate in treating patients with advanced or metastatic solid&#xD;
      tumors or refractory or relapsed acute myeloid leukemia. Entinostat and sorafenib tosylate&#xD;
      may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum-tolerated dose of entinostat in combination with sorafenib&#xD;
      tosylate in patients with advanced, inoperable, or metastatic solid tumors.&#xD;
&#xD;
      II. To determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the pharmacokinetic profile of this regimen in patients with&#xD;
      refractory/relapsed acute myeloid leukemia (AML).&#xD;
&#xD;
      II. To assess the preliminary anti-tumor activity of this regimen in patients with advanced,&#xD;
      inoperable, or metastatic solid tumors or refractory/relapsed AML.&#xD;
&#xD;
      III. To evaluate histone deacetylase (HDAC) inhibition of histone acetylation in leukemia&#xD;
      blast cells.&#xD;
&#xD;
      TERTIARY OBJECTIVES (EXPLORATORY):&#xD;
&#xD;
      I. To evaluate the expression of downstream markers of drug activity such as p38, MCL-1,&#xD;
      FLT-3, and VEGFR-2 in leukemia blast cells.&#xD;
&#xD;
      II. To evaluate SNDX-induced expression of p21^WAF1/CIP1 in leukemia blast cells.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of entinostat.&#xD;
&#xD;
      Patients receive oral entinostat once daily on days 1 and 15 and oral sorafenib tosylate&#xD;
      twice daily on days 1-28 (days 15-28 only of course 1). Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients in the expansion cohort undergo blood, bone marrow aspiration, or biopsy for&#xD;
      pharmacokinetic studies and biomarker analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed up for up to 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by the NCI CTCAE version 4.0</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of sorafenib tosylate</measure>
    <time_frame>At baseline, and at days 15, 16, and 28 of course 1, and day 1 of course 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of entinostat</measure>
    <time_frame>At baseline and at days 1, 8, 15, 16, and 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) based on the best overall response recorded for each patients or according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>For ORR the 95% confidence interval will be estimated. The 95% confidence interval for percent of patients in each RECIST response category (i.e., CR, PR, SD, and PD) and disease control rate will also be estimated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Adult Acute Basophilic Leukemia</condition>
  <condition>Adult Acute Eosinophilic Leukemia</condition>
  <condition>Adult Acute Megakaryoblastic Leukemia (M7)</condition>
  <condition>Adult Acute Minimally Differentiated Myeloid Leukemia (M0)</condition>
  <condition>Adult Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Adult Acute Monocytic Leukemia (M5b)</condition>
  <condition>Adult Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Adult Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (entinostat, sorafenib tosylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral entinostat once daily on days 1 and 15 and oral sorafenib tosylate twice daily on days 1-28 (days 15-28 only of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entinostat</intervention_name>
    <description>Given orally (PO)</description>
    <arm_group_label>Treatment (entinostat, sorafenib tosylate)</arm_group_label>
    <other_name>HDAC inhibitor SNDX-275</other_name>
    <other_name>SNDX-275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (entinostat, sorafenib tosylate)</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat, sorafenib tosylate)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat, sorafenib tosylate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must meet 1 of the following criteria:&#xD;
&#xD;
               -  Histologically or cytologically confirmed solid tumors (dose-escalation only)&#xD;
&#xD;
                    -  Locally advanced, inoperable, or metastatic disease&#xD;
&#xD;
                    -  Evaluable or measurable disease&#xD;
&#xD;
               -  Diagnosis of acute myeloid leukemia (AML) for which no other standard therapy,&#xD;
                  including stem cell transplantation, is expected to result in meaningful clinical&#xD;
                  response (expansion cohort only)&#xD;
&#xD;
                    -  Refractory or relapsed disease&#xD;
&#xD;
                    -  Chronic myelogenous leukemia in blast crisis allowed&#xD;
&#xD;
                    -  No acute promyelocytic leukemia with t(15;17)&#xD;
&#xD;
                    -  Must consent to have fresh tumor, bone marrow aspirate, and biopsy obtained&#xD;
&#xD;
          -  No untreated, symptomatic, or unstable brain metastases&#xD;
&#xD;
          -  No active CNS involvement for patients with AML&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³ (dose-escalation only)&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³ (dose-escalation only)&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL (dose-escalation only)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 3 times ULN (≤ 5 times ULN for liver metastasis)&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  Albumin &gt; 3.0 g/dL&#xD;
&#xD;
          -  Plasma phosphorus &gt; lower limit of normal (with supplementation)&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
          -  APTT ≤ 1.5 times ULN (if not on anticoagulants)&#xD;
&#xD;
          -  Able to swallow oral medications&#xD;
&#xD;
          -  ≥ 16 years old (expanded cohort patients recruited at the University of Colorado site)&#xD;
&#xD;
          -  Must have tolerated prior sorafenib tosylate (dose: 400 mg twice daily), if applicable&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-barrier contraception during the study and&#xD;
             for 90 days after completion of study therapy&#xD;
&#xD;
          -  No history of cardiac disease, including any of the following:&#xD;
&#xD;
               -  NYHA class II-IV congestive heart failure&#xD;
&#xD;
               -  Active coronary artery disease&#xD;
&#xD;
               -  Prior diagnosis of bradycardia or other cardiac arrhythmia defined as ≥ grade 2&#xD;
                  or uncontrolled hypertension&#xD;
&#xD;
               -  Myocardial infarction (MI) within the past 6 months&#xD;
&#xD;
               -  Persistent tachycardia&#xD;
&#xD;
               -  LVEF &lt; 40% by MUGA&#xD;
&#xD;
               -  Second- or third-degree heart block&#xD;
&#xD;
               -  QTc &gt; 490 msec&#xD;
&#xD;
               -  ST-T wave changes consistent with acute MI or acute ischemia&#xD;
&#xD;
          -  No clinically active serious infections defined as ≥ grade 2&#xD;
&#xD;
          -  No substance abuse, medical, psychological, or social conditions that may, in the&#xD;
             opinion of the Investigator, interfere with the patient's participation or evaluation&#xD;
             of the study results&#xD;
&#xD;
          -  No condition that is unstable or that could jeopardize the safety of the patient and&#xD;
             his/her study compliance&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  No significant gastrointestinal disorder that, in the opinion of the Investigator,&#xD;
             could interfere with the absorption of entinostat and/or sorafenib tosylate including&#xD;
             any of the following:&#xD;
&#xD;
               -  Significant, uncontrolled inflammatory bowel disease&#xD;
&#xD;
               -  Abdominal fistula or gastrointestinal perforation within the past 6 months&#xD;
&#xD;
               -  Extensive small bowel resection&#xD;
&#xD;
               -  Requiring tube feeding or parenteral hydration and/or nutrition&#xD;
&#xD;
          -  No concurrent immunosuppressive therapies, including high-dose systemic&#xD;
             corticosteroids (&gt; 0.5 mg/kg/day prednisone or equivalent) unless used intermittently&#xD;
             or as a tapered course for ≤ 4 weeks&#xD;
&#xD;
          -  Concurrent hydroxyurea and/or anagrelide allowed&#xD;
&#xD;
          -  Concurrent warfarin allowed provided the dose has been stable for the past 2 months&#xD;
             and INR has been between 2 and 3&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy, immunotherapy, or investigational agents&#xD;
             (=&lt; 2 weeks for leukemia patients in expansion cohort)&#xD;
&#xD;
          -  More than 2 weeks since prior palliative radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since major surgery&#xD;
&#xD;
          -  More than 2 weeks since minor surgery (e.g., talc pleurodesis, excisional biopsy,&#xD;
             etc.)&#xD;
&#xD;
          -  Concurrent hormonal therapies (e.g., LHRH antagonists, megestrol, octreotide,&#xD;
             calcitonin, etc.) allowed&#xD;
&#xD;
          -  No concurrent strong CYP3A4 inducers or inhibitors, including, but not limited to, any&#xD;
             of the following:&#xD;
&#xD;
               -  Valproic acid&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Grapefruit&#xD;
&#xD;
          -  No other concurrent anticancer therapy including chemotherapy, radiotherapy (including&#xD;
             palliative), or immunotherapy (except hydroxyurea in leukemia patients during course&#xD;
             1)&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Adjei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <last_update_submitted>September 18, 2013</last_update_submitted>
  <last_update_submitted_qc>September 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Basophilic, Acute</mesh_term>
    <mesh_term>Leukemia, Eosinophilic, Acute</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Entinostat</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

